Table 5. Clinical outcomes with different CYP2C19 genotypes at one year follow-up.

Adverse Events	Normal metabolizer (n = 272)	Intermediate metabolizer (n = 281)	Poor metabolizer (n = 62)	P-value
Values expressed are in n (%). MACCEs major adverse cardiac and cerebrovascular event, includes cardiac death, stent thrombosis, repeat revascularization, MI and stroke, MI myocardial infarction. MI: myocardial infarction. aP < 0.05 vs. NCLR group, bP < 0.05 vs. Ticagrelor group, cP < 0.05 vs. Clopidogrel group..
All-cause death	5 (1.8%)	6 (2.1%)	1 (1.6%)	0.948
MACCEs	29 (10.7%)	46a (16.4%)	14a (22.6%)	0.026
Cardiac death	4 (1.5%)	4 (1.4%)	1 (1.6%)	0.994
Stent thrombosis	10 (3.7%)	15 (5.3%)	4 (6.5%)	0.519
MI	6b,c (2.2%)	13a,c (4.6%)	6ab (9.7%)	0.034
Repeat revascularization	9 (3.3%)	12 (4.3%)	2 (3.2%)	0.817
Stroke	0 (-)	2 (0.7%)	1 (1.6%)	0.141
Massive bleeding	3 (1.1%)	4 (1.4%)	1 (1.6%)	0.922
Moderate bleeding	13 (4.8%)	4 (1.4%)	3 (4.8%)	0.051
Small bleeding	19 (7.0%)	24 (8.5%)	4 (6.5%)	0.736